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Objective: To analyze the misoprostol use in pregnancies with intrauterine fetal death (IUFD),
considering  mode of delivery and induction-delivery interval.
Methods:  Descriptive study including 171 pregnant women with IUFD, in the second or
third  trimester, submitted to labor induction with vaginal misoprostol and/or induc-
tion/augmentation with intravenous oxytocin, from 2005 to 2008, at a teaching-hospital
of  the Brazilian Uniﬁed Health System (Sistema Único de Saúde - SUS).
Results:  Misoprostol alone (treatment A), misoprostol plus oxytocin (treatment B), and
oxytocin  alone (treatment C) were administered in 9.3%, 19.9%, and 70.8% of the cases,
respectively.  One-third of pregnancies were less than 28 weeks, and 2.9% required a cae-
sarean  section. The percentage of vaginal delivery in treatments A and B combined (98.0%)
was  similar to treatment C (96.7%). The mean induction-delivery interval was  15.4 hours.
Comparing  multiple groups, the mean induction-delivery interval was signiﬁcantly shorter
in  treatment A (20.1 hours) than in treatment B (33.3 hours), and was  longer than in
treatment  C (9.7 hours). The majority (71%) of cases required a single administration of
misoprostol, and the total dosage was lower in treatment A (mean: 98.4 g) compared with
treatment  B (mean: 157.0 g).
Conclusion: Misoprostol effectively contributed to delivery of IUFD by vaginal route assisted
under  routine conditions of a public health service in Brazil, demonstrating its importance
in  cases resistant to usual induction methods, and its availability in Brazilian public health
services  is recommended.
Uso  de  misoprostol  na  rotina  para  terminar  gestac¸ões  com  feto  morto
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Objetivo: Descrever o uso de misoprostol em gestac¸ões  com óbito fetal intraútero, con-
siderando  o tipo de parto e o intervalo induc¸ão-parto.
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Ocitocina
Trabalho de parto induzido
Parto  obstétrico
Óbito fetal
Feto  morto
Métodos: Estudo descritivo de 171 gestantes com óbito fetal intraútero, no segundo ou ter-
ceiro trimestres, submetidas à induc¸ão  do parto com misoprostol vaginal ou acelerac¸ão  do
parto com ocitocina parenteral, de 2005 a 2008 em um hospital-escola do Sistema Único de
Saúde (SUS) do Brasil.
Resultados:  Misoprostol isolado (tratamento A), misoprostol complementado pela ocitocina
(tratamento B) e ocitocina isolada (tratamento C) foram administrados em 9,3%, 19,9%
e 70,8% dos casos, respectivamente. Um terc¸o  das gestac¸ões  estavam com menos de 28
semanas e 2,9% delas requereram operac¸ão  cesariana. O percentual de parto vaginal nos
tratamentos A e B combinados (98,0%) foi similar ao tratamento C (96,7%). A média do inter-
valo induc¸ão-parto  foi menor no tratamento A (20,15 horas; DP = 15,8 horas) comparado ao
tratamento B (33,31 horas; DP = 29,6 horas) e a proporc¸ão  de partos pela via vaginal ocorridos
dentro de 48 horas foi de 100% (tratamento A), 96,7% (tratamento B) e 96,7% (tratamento C).
A maioria dos casos (71%) tratados com misoprostol requereu uma  única administrac¸ão  da
droga e a média da dosagem total foi menor no tratamento A (média 98,4 g) comparado ao
tratamento B (média: 157,0 g).
Conclusão: Misoprostol efetivamente contribuiu para a resoluc¸ão  de gestac¸ões  com óbito
fetal intraútero, mostrando a importância de sua aplicac¸ão  em casos resistentes aos méto-
dos usuais de induc¸ão  e de sua disponibilizac¸ão  nos servic¸os  públicos de saúde no Brasil.
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13 Entroduction
he effectiveness of misoprostol for labor induction has been
idely  demonstrated by several randomized controlled trials
RCTs),1 but the absence of its registration for obstetrical and
ynecological applications remains an important problem in
ost countries.2 Currently, Brazil and Peru are the only Latin-
merican  countries to make misoprostol ofﬁcially licensed
or  reproductive health indications. In Brazil, misoprostol is
pproved for vaginal use, and the preparation is indicated in
ases  when it is necessary to induce labor in a full-term or near
ull-term  pregnancy, to induce labor of retained dead fetus, or
n the case of legal abortions.3
Despite ofﬁcial regulation by government, the irregular
upply of misoprostol is still a barrier in Brazil, which might
imit  its access4 and in turn lead health professionals to make
ifﬁcult  choices regarding the treatments to be administered
nd/or opt for a suboptimal amount of misoprostol.5 Addi-
ionally,  the use of misoprostol in the presence of a previous
terine  scar6 and/or previous caesarean section increases the
isk  of uterine rupture.7
As the lack of license for certain misoprostol obstetrical
ndications is not a problem in Brazil, experiences other than
CT  may  contribute to increase the understanding of the
ubject,  especially if the focus is on medical labor induction
racticed in low-resource environments. Thus, the objective of
his  study was  to describe the use of misoprostol in pregnan-
ies  with intrauterine fetal death (IUFD), in the second or third
rimester,  regarding mode of delivery and induction-delivery
nterval.
ethods
© 20his was  a descriptive study carried out with pregnant women
ith  IUFD who were submitted to medical labor induction
rom January of 2005 to December of 2008 at a teachinghospital of the Brazilian Uniﬁed Health System (Sistema Único
de  Saúde – SUS).
Study  population
According to the Brazilian Mortality Information System,
410  singleton gestations with dead fetuses registered at
the  aforementioned hospital were over 499 g birth weight
and/or  ≥ 22 weeks of gestational age, and thus were eli-
gible  for this study. Initially a total of 219 women were
excluded for the following reasons: postpartum admis-
sion  (15), emergency C-section (98), spontaneous deliveries
(104),  or use of Foley catheter followed by a C-section
(2). The inclusion criteria for medical labor induction
and/or augmentation with medications was  fulﬁlled by
191  pregnant women. Of these, 20 were also excluded
for the following reasons: (i) eight cases of medical
induction in simultaneous use of Foley catheter method;
(ii)  ten cases of clinical induction initiated when the
fetus  was  still alive (one anencephalic, one unexplained
death, and eight cases of chorioamnionitis); (iii) two
cases  of loss of information about fetal vitality at the beginning
of  induction. The current study comprised 171 patients who
received  medical treatment for labor induction with vaginal
misoprostol or labor augmentation with intravenous oxytocin
infusion.
The  medical treatment for labor induction or labor
augmentation to terminate IUFD pregnancies is routinely per-
formed  in this hospital with misoprostol and/or oxytocin.
Misoprostol is indicated for unfavorable cervix considering
length, position, dilation, and station, and is exclusively
administered vaginally. A favorable or mature cervix is that
with  2 cm of dilation, 80%effaced, soft, and in midposition,
and with a fetal occiput at −1 station, with a prognosis of
8
lsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDvaginal  delivery; otherwise, the cervix is classiﬁed as imma-
ture  or unfavorable. When the cervix becomes favorable, the
intravenous  oxytocin infusion is performed to supplement
previously administered misoprostol. In contrast, oxytocin
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required a single administration of the medication (range:
one  to four administrations). Among the cases with a single356  r e v a s s o c m e d b r
alone is recommended for augmentation of spontaneously
initiated labor or to supplement the induction with misopros-
tol.  The oxytocin infusion is administered in 500 mL of 5%
glucose,  intravenously, with initial dose of 2 mIU  per minute,
increasing until the uterus attains a level of activity similar to
the physiological.
The mode of delivery (vaginal or caesarean section) and
the  induction-delivery interval were  the two main outcomes
studied.  The induction-delivery interval comprises the inter-
val  between the beginning of induction or augmentation with
use  of medication and the fetus expulsion. This interval was
measured  in hours, and evaluated both as continuous and cat-
egorical variables, based on two categories (≤ 48 hours and >
48 hours).
The  following medical treatments were  considered: miso-
prostol  alone (treatment A), misoprostol supplemented with
oxytocin  (treatment B), and oxytocin alone (treatment C).
Besides  the mode of delivery and induction-delivery interval,
the  total dose of misoprostol (in g), the number of misopros-
tol  administrations, and complementation with postpartum
curettage were  also analyzed.
The maternal/obstetric characteristics selected were
maternal age (< 20 years; 20 to 34 years; 35 and over); nulli-
parity  (yes/no); gestational age (< 28/≥ 28 weeks); previous
caesarean section (yes/no); immature cervix (yes/no); and
intact  amniotic membranes (yes/no).
Statistical analysis was  performed using the statistical
package R. The continuous variables were  expressed as mean
and  standard deviation (SD), and categorical variables were
expressed  as frequency and percentage.This study follows the principles of the Declaration of
Helsinki, and was  approved by the research ethics committee
of  the teaching hospital under No. 21/2009.
Table 1 – Maternal and obstetrical characteristics of 171 pregna
induction or labor augmentation
Variable Treatment A
Misoprostol alone
Yes  (n = 16)
n (%)
Maternal age (years)
13-19  6 (37.5) 
20-34 10 (62.5) 
≥ 35 0 (0) 
Nulliparity
Yes 7 (43.7) 
No 9 (56.3) 
Prior cesarean section* (n = 170)
Yes 3  (18.7) 
No 13 (81.3) 
Gestational age* (n = 167)
≤ 27 weeks 6 (37.5) 
≥ 28 weeks 10 (62.5) 
Cervix status* (n = 170)
Immature 16 (100.0) 
Mature 0 (0) 
∗ Results exclude women with incomplete data. 0 1 3;5  9(4):354–359
Results
One hundred and seventy-one cases of IUFD gestations were
analyzed.  Misoprostol was administered in 29.2% of the cases.
All  administrations of misoprostol were performed by vagi-
nal  route, 32% of which were misoprostol alone (treatment A),
and  68% of which were  supplemented with intravenous oxy-
tocin  (treatment B). Oxytocin alone (treatment C) was  given
in  70.8% of cases. The means maternal age and gestational
age  were 26.1 years (SD = 7.6 years; range: 14 to 46 years) and
30.7  weeks (SD = 5.4 weeks; range: 18 to 42 weeks), respectively.
One-third of the pregnancies were less than 28 weeks, and
the  mean birth weight was  1,707.2 g (SD = 967.1 g; range: 465 to
5,760 g). All mothers in the misoprostol groups (treatment A or
treatment B), and 79.1% of those in the oxytocin group (treat-
ment  C) had intact amniotic membranes. Unfavorable cervix
was  the main maternal/obstetrical characteristic found in the
treatment  A group (100.0%) and treatment B group (97.1%)
(Table  1).
The  contribution for vaginal delivery of treatments A and
B  combined was  as high as treatment C (98.0% vs. 96.7%). C-
section  occurred in one out of 34 mothers of the treatment
B  group, and in four out of 121 mothers of the treatment C
group.  The relation between the type of treatment and mode of
delivery  revealed that misoprostol alone and misoprostol sup-
plemented  by oxytocin had a similar effect to that of oxytocin
alone  (Table 2).
The  majority (71%) of cases treated with misoprostoladministration, 75.0% and 69.7% were from group A and group
B,  respectively. Repeated administrations were performed
ncies with intrauterine fetal death, by type of labor
Treatment B
Misoprostol plus oxytocin
Yes (n = 34)
n (%)
Treatment  C
Oxytocin alone
Yes (n = 121)
n  (%)
11 (32.3) 26 (21.5)
16 (47.1) 75 (62.0)
7 (20.6) 20 (16.5)
17 (50.0) 44 (36.4)
17 (50.0) 77 (63.6)
6 (17.6) 18 (15.0)
28 (82.4) 102 (85.0)
12 (35.3) 37 (31.6)
22 (64.7) 80 (68.4)
33 (97.1) 57 (47.5)
1 (2.9) 63 (52.5)
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Table 2 – Mode of delivery of 171 pregnancies with intrauterine fetal death, by type of treatment for labor induction
or labor augmentation
Type of treatment Type of delivery Total (n)
Vaginal (n = 166)
n (%)
Cesarean  section
(n  = 5)
n (%)
Misoprostol in separate categories
Treatment  A (misoprostol alone) 16 (100.0) 0 (0) 16
Treatment B (misoprostol plus ocytocin) 33 (97.1) 1 (2.9) 34
Treatment C (Oxyciton) 117 (96.7) 4 (3.3) 121
Misoprostol in combined categories
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Treatment C (Oxyciton) 117 (96.7
wice (6.2% vs. 18.1%), three times (12.5% vs. 6.1%), and four
imes  (6.2% vs. 6.1%) in group A and group B, respectively.
otal value of dosage varied between 25 g to 400 g in the
reatment A (mean: 98.4 g; SD = 92.8) and treatment B groups
mean:  157.0 g; SD = 92.7).
Forty  percent of the women  who  received treatment with
isoprostol underwent postpartum curettage. The procedure
as  less common in the treatment A group (31.2%) than in the
reatment  B group (44.1%). Overall, 62% of the patients with
ess  than 28 weeks of gestational age underwent this surgical
ntervention.
The  mean induction-delivery interval for the entire group
as  15.37 hours (SD = 19.4 hours; range: 0.25 to 165 hours).
onsidering particular groups, the means were 20.15 hours
treatment  A), 33.31 hours (treatment B) and 9.70 hours (treat-
ent  C) (Table 3).
At  the end of 48 hours, 96% of the pregnancies were  ter-
inated, the majority of them (95.8%) by vaginal route. The
roportions  of cases treated with misoprostol alone, miso-
rostol  plus oxytocin, and oxytocin alone who delivered
aginally within 48 hours were  100%, 96.7%, and 96.7%, respec-
ively.
iscussion
nlike ﬁndings based on RCTs conducted under ideal con-
itions,  the present results reﬂect the role of misoprostol in
bstetrics  as practiced under the challenging conditions rou-
inely  faced in the public health services of the SUS. In these
ircumstances, misoprostol helped to resolve more  unfavor-
ble  clinical cases presenting cervical immaturity and intact
mniotic  membrane, since the oxytocin group also included
regnant women  in advanced stages of cervical dilation. The
Table 3 – Mean induction-delivery interval of 171 pregnancies w
induction or labor augmentation.
Type of treatment n (%) Mean (
Treatment A (misoprostol alone) 16 (9.3) 20.1
Treatment B (misoprostol plus oxytocin) 34 (19.9) 33.3
Treatment C (oxytocin alone) 121 (70.8) 9.7
SD, standard deviation.1 (2.0) 50
4 (3.3) 121
low number of induction failures and C-sections demon-
strated the importance of misoprostol in the resolution of
IUFD  cases, in the second or third trimester, especially in low-
income  settings.
Comparing with other studies,9–12 the present cases were
resolved with a relatively lower mean total dose of misopros-
tol  and a single administration. Other studies13 report 400 g
to  600 g of the preparation to have been effective in achiev-
ing  uterine evacuation within 24 to 48 hours, and that lower
doses  prolonged the induction-delivery interval. Despite the
prolonged  induction-delivery interval observed in the present
study,  the lower number of administrations may  have reduced
the  physical discomfort for a large number of these women,
already  distressed by the fetal death, since they had to endure
only  a single pelvic exam for the administration of vaginal
misoprostol.
The  present study included women with one (19/27), two
(6/27),  and three (2/27) prior C-sections (of any type), there-
fore  having an increased risk for uterine rupture,7 although
this  complication did not occur. Careful patient selection, indi-
vidualization of doses administered, adequate monitoring of
induction-delivery interval, and especially, the few cases with
the  combination of previous C-section and administration of
misoprostol  may  have contributed to such results. Accord-
ing  to Ramirez et al.,14 3.4% of the women who  had uterine
scarring and were  submitted to medical labor induction for
the  assisted delivery of a dead fetus experienced uterine rup-
ture  in 19 American institutions. Although Ramirez et al.14
have emphasized that uterine rupture did not show associ-
ation  with any drug employed, it is possible that it increases
maternal morbidity/mortality in this scenario.
Overall, the frequency of previous C-section was  greater
than  15% considering all women, as well as in each treat-
ment  group analyzed per se. Generally, with fetal death, there
ith intrauterine fetal death, by type of treatment for labor
hours) SD Minimum value Maximum value
5 15.8 4 60
1 29.6 6 165
0 11.6 0.25 75
 a s . 2
r358  r e v a s s o c m e d b r
are reports in Brazil that a previous uterine scar reduces by
84%  (OR 0.16; 95% CI: 0.04-0.71) the chance for drug-induced
labor,15 and increases by seven-fold (OR 7.0; 95% CI: 2.29-21.55)
the  chance for a repeat C-section as the route to deliver the
dead  fetus.16 In the present study, none of the cases requiring
a  C-section was  from the misoprostol alone group, as was  also
observed by Aquino et al.10 However, one case with a previous
C-section submitted to treatment B resulted in induction fail-
ure.  In the treatment C cases, the C-section was  conducted to
guarantee the safety of the mother when the management of
labor  was  affected by prior multiple cesarean deliveries (one
case),  systemic lupus erythematosus (one case), macrosomic
fetus  weighting 5,760 g (one case), and placental abruption
associated with severe gestational hypertension (one case).
In  the present study, postpartum curettage was  much  more
frequent  when compared with C-sections, but similar to other
studies  in proportion (40%).17 It was  used to check for placental
residue  retention, suspected by a clinical exam and/or imag-
ing.  Although postpartum curettage was  not the objective of
this  study, it is important to highlight that early gestational
age  appears to inﬂuence the need for the procedure,17 which
was  performed in over 60% of the patients with gestational
age  under 28 weeks.
As  observed by others,18–21 in the present study the vast
majority of cases were  delivered vaginally within 48 hours;
however,  the mean induction-delivery intervals were higher
in  the misoprostol groups than in the oxytocin group, as was
found  by Aquino et al.10 It probably occurred because the oxy-
tocin  group had both women in situations which favored the
labor  induction and women  whose labor had spontaneously
started, and the labor was  simply augmented by employing
the  drug, which partially explains the mean interval found.
Also,  lack of achievement of fetal expulsion within 48 hours
did  not extend to C-section, and four out of the seven more
prolonged cases were  from the treatment B group; however,
misoprostol was  applied according to the protocol in only
one  of those four cases. According to Victora et al.,22 in the
standard  clinical trial model, measures are taken for ensuring
ideal  compliance, including intensively trained staff, strictly
controlled  dosages, strong supervision, and monitoring of side
effects. Such measures cannot be easily replicated under rou-
tine  conditions. Despite the evidence, misoprostol was also
initiated  after oxytocin (three cases), creating a group of much
worse  prognosis (group B). The non-observance of the hospital
protocols  and the unavailability of the drug may  have been rea-
sons for such conduct. However, these questions are beyond
the  scope of the present study.
This study has limitations. Firstly, this was  a retrospective
descriptive study, with data collection dependent on the com-
pleteness  of medical forms, making it impossible to analyze
characteristics such as schooling and household income. This
issue did not appear to affect the study results, since all par-
ticipants  were  selected from a single public health service,
possibly  reﬂecting the socioeconomic status of women that
attend  SUS units in the region. Secondly, Bishop’s score infor-
mation  was  not available, so the option was  made for using
cervix  description (mature or immature) instead. Although
insufﬁcient to replace the aforementioned index, this char-
acteristic  aided in the clinical classiﬁcation of the cases at
hand.  Thirdly, it was  not possible to classify some complaints 0 1 3;5  9(4):354–359
occasionally reported on the medical charts as side effects
of  misoprostol, even though there are reports9 that vomiting,
nausea,  fever, headache, and diarrhea are less common in the
vaginal  route than in the oral route. Finally, the major issue
was  the creation of the speciﬁc groups. Although uterus evacu-
ation  was the main goal in all groups, the cervix characteristics
were different. Unfortunately, the oxytocin group was  com-
posed  of women in advanced stages of cervical dilation, which
made  comparison among the groups difﬁcult. The option was
to  show the results employing a descriptive design.
As  advantages, this study was  performed at a government-
funded health service, which not only is a reference
maternity-hospital for high-risk pregnancies, but also receives
a  wide variety of patients, and therefore better reﬂects the
assistential reality of the SUS, as well as the proﬁle of the
assisted  population. Taking into account the focus on dead
fetus  delivery, the size of the study population can be consid-
ered  large.
Therefore, the induction of the delivery of dead fetuses
was  successful, reinforcing the utilization of misoprostol in
government-provided healthcare services, and its ultimate
incorporation in the treatment of cases in which oxytocin has
not  been successful. Nonetheless, its use must be carefully
evaluated, guided by evidence-based protocols, and monitored
by  professionals capable of managing any occurrence associ-
ated  with the induction. In relation to other Latin-American
countries, the availability of misoprostol for vaginal admin-
istration  in Brazil may  be considered an advance. However,
additional concerns might result from situations such as: (i)
distribution  restricted by law to hospitals,4 (ii) expensive com-
mercialization price, and (iii) product manufactured by only
one  local pharmaceutical company.3 Such problems related
to  the supply chain of misoprostol may  constitute obstacles
for  the renovation of the product’s license, which may  in the
future  result in the reduction of access to the medication
already guaranteed for some indications in the ﬁeld of repro-
ductive  health in Brazil.
Conclusion
In conclusion, misoprostol effectively contributed to the
success  of vaginal deliveries of dead fetuses, showing the
importance of its application to resolve the cases presenting
difﬁculty with the usual induction methods, and of its avail-
ability  in public health services in Brazil.
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